Daraxonrasib stopped tumour growth in 90% of 61 participants with advanced pancreatic cancer during a recent trial. Dr. Wungki Kettering reported that over 60% of patients saw tumours shrink or disappear, with some becoming undetectable on CT scans after receiving the pill and chemotherapy.
Read More »: Daraxonrasib stops tumour growth in 90% of pancreatic cancer patients

